http://news.bmn.com/conferences/list/view?rp=2001-ICI-4-S1

 

ICI 2001 - Day 4 - Thursday 26 July 2001


 

Report:

Immune defenses never forget antigen

Investigator: Peter Doherty

 

Thursday Jul 26th, 2001

by Julie Clayton

 

 

The "memory" of a virus infection - a phenomenon that supplies a rapid reaction force in the immune system ready to eliminate the same virus at the next encounter - can last a lifetime without the need for a "top-up" encounter. The claim, backed by new data presented today, contradicts immunological dogma.

"Immunologists seem to believe in mythology," said Peter Doherty, of the St. Jude Children's Research Hospital in Memphis, Tennessee. "Once embedded in the literature there seems to be no way of getting rid of it," he told BioMedNet News.

The findings directly challenge a scientific dogma that has arisen over the past two decades. The dogma states that to keep alive a vital stock of "memory" T cells - the arm of the immune system that targets pathogens in an exquisitely specific manner - the T cells need somehow to continue to "see" a fragment of their target antigen, stored somewhere in the body.

Nobel prizewinner Rolf Zinkernagel, of the Institute for Experimental Immunology in Zurich, is a particular champion of the antigen persistence idea.

This idea proposes that fragments of virus may be sequestered away in the lymph nodes. Here, memory T cells with the ability to kill virus-infected cells, called CD8 T cells, are likely to "traffic-through" and receive a "top-up" stimulus with their specific antigen. Zinkernagel's data derive from a mouse model of virus infection, with the lymphocyte choriomeningitis virus, or LCMV.

But Doherty, who shared the Nobel prize with Zinkernagel for joint work they performed in the 1970s, has since developed a mouse model for infection with influenza virus, with quite different results.

Doherty now reports that rather than expand and die rapidly, after beating off a viral infection, influenza-specific CD8 memory T cells persist for a far longer time than previously thought. Most significantly, Doherty says, this is after the the virus has been completely eliminated, with no fragments remaining.

"There's a lot of stuff embedded in the literature about this that's wrong, but it's become paradigms. For example, the idea that most (90 or 98% of) T cells die after the acute response doesn't seem to be right. But you keep seeing this idea over and over again," he said.

Using more precise measures of T cell numbers than were previously available, Doherty has discovered that more memory T cells survive than originally thought. But what keeps them alive is a highly contentious issue.

"In the Proceedings of the National Academy of Sciences we reported that if you look at a whole mouse rather than just a selected site, the number of cells in the site of virus growth falls quickly, but elsewhere the numbers fall more slowly. But there seems to be no way of getting this message across," Doherty said.

Jonathan Sprent, of the Scripps Institute for Research in La Jolla, California, reported to the same audience that chemical signals, in the form of the cytokine IL15, are sufficient to keep CD8 memory T cells alive.

He showed that many cells of the immune system are likely to release IL15 in vitro, but "what makes it under normal physiological conditions is unclear, although it maybe dendritic cells" he told BioMedNet News.

Dendritic cells, in turn, are usually stimulated by the presence of invading pathogens, and represent a link between first-line defenses and the longer-term T cell response to antigens. But a direct link between bacterial infection and the maintenance of T cell memory remains to be seen.

The important feature, according to Sprent, is that memory T cells are highly sensitive to stimulation by cytokines.

Doherty also questions the origin of memory T cells - whether they arise from cells that are simply dividing as a result of an encounter with a virus antigen, or whether they arise from T cells that have developed beyond this cell division stage to become differentiated "killer" T cells, which destroy virus-infected cells.

"The idea that effector cells become memory cells is almost certainly wrong. It's the activated T cell that becomes a memory cell," he told BioMedNet News. "I think we're getting a much better understanding of what a memory T cell is," he concluded.

ICI 2001
11th International Congress of Immunology - Scandinavian Society for Immunology

 


Contents

Day: 

 1 

 2 

 3 

 4 

 5 



Day 4 Reports:
(Investigator's name)


Immune defenses never forget antigen
(Peter Doherty)


License to kill
(Cornelis Melief )


Breeding vaccines for Dengue
(Juha Punnonen)


Protecting against diabetes is a fluke
(Anne Cooke)


Leading immunologist questions TB vaccine safety
(Ian Orme, Douglas Lowrie, and Carol Nacy)


The antigen persistence debate persists
(Rolf Zinkernagel and Rafi Ahmed)


Day 4 Profiles:


Rolf Zinkernagel


Peter Doherty


Margaret Liu


View all Profiles


ICI Site

 

Printer ready version
E-mail article to a friend

See also:

CD1-specific T cells in microbial immunity
[Review]
Jenny E. Gumperz and Michael B. Brenner
Current Opinion in Immunology, 2001, 13:4:471-478

Dendritic cell subsets and costimulation for effector T-cell responses
[Review]
Peter J.L. Lane and Fiona M. McConnell
Current Opinion in Pharmacology, 2001, 1:4:409-416

Related links on other sites:

Doherty's research group
at St Jude Children's Research Hospital, Memphis

 

Printer ready version
E-mail article to a friend


ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.